APOE
If any of the terms on this page are unclear or you want to learn more about them click here!
APOE is the most important risk gene for late-onset Alzheimer’s disease. It does not usually cause Alzheimer’s in the way that APP or PSEN1 mutations can cause familial early-onset disease. Instead, different APOE versions change a person’s risk and timing, with the APOE ε4 variant increasing risk and tending to shift disease onset earlier.
Normal function
APOE encodes apolipoprotein E, a transport protein that helps move cholesterol and other lipids between cells, especially in the brain. This matters because neurons rely on tightly controlled lipid handling for membrane structure, synapse function, and damage repair. APOE also influences how the brain responds to injury and how certain proteins, including amyloid-beta, are cleared.
Mutation and effect
APOE is usually discussed in terms of alleles rather than classic disease-causing mutations. The three main human isoforms are ε2, ε3, and ε4. APOE ε4 is associated with increased Alzheimer’s risk, while ε2 is often relatively protective. APOE ε4 appears to alter lipid handling, amyloid pathology, inflammation, and neuronal resilience in ways that make the brain more vulnerable over time.
Key mechanisms involved
APOE ε4 influences Alzheimer’s disease through several interconnected biological processes. Rather than acting through a single pathway, it changes the overall cellular environment in ways that make the brain more vulnerable to damage over time. One of the ways it does this is by making cells less effective at clearing amyloid beta, meaning aggregates (clumps of proteins) are more likely to remain and grow. Because of its role in trafficking cholesterol, APOE ε4 can contribute to disease symptoms by making synapses less functional more vulnerable. Finally, it can push immune cells like microglia and astrocytes into a more inflammatory state, contributing to damage over time.
Implications for treatment
Compared with average late-onset Alzheimer’s disease, APOE ε4-associated disease tends to show earlier and greater amyloid burden (a larger amount of abnormal protein clumps) and often faster cognitive decline at the population level, although there is still major person-to-person variation. The pathology remains Alzheimer’s disease, but APOE status can shape how strongly certain downstream processes appear.
APOE has become increasingly important in the treatment landscape, because genotype may influence both risk counseling and potentially response or safety profiles for anti-amyloid therapy. It is also driving development of APOE-targeted strategies aimed at changing lipid biology, inflammation, or amyloid handling (how the body produces, clears, and breaks down amyloid).
Research focus
Current research focuses on how APOE ε4 changes brain metabolism, amyloid deposition, inflammation, and treatment response. APOE is also central to precision-medicine efforts, where genetic background may help define different Alzheimer’s subtypes and intervention strategies.
Inheritance
APOE isn't a broken gene, but more like a dial that turns Alzheimer's risk up or down depending on which version you have. Having one "risky" copy (called ε4) raises your odds a few times over baseline; having two copies raises it much further. Around 40% of people with Alzheimer’s carry the APOE ε4 variant. Carrying other versions of the APOE gene (specifically ε2) actually reduce your risk of Alzheimer’s. It's inherited the ordinary way: 50/50 odds from a parent who carries it. But, even having two copies isn't a guarantee you'll get sick.
Sources
- Yamazaki, Y., Zhao, N., Caulfield, T. R., Liu, C.-C., & Bu, G. (2019). Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies.
- Serrano-Pozo, A., Das, S., & Hyman, B. T. (2021). APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches.
- Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024). Multifaceted roles of APOE in Alzheimer disease.
- Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.